A Case of Angioimmunoblastic T-cell Lymphoma Arising in the Cervical Region

• Published in: Nippon Jibi Inkoka Gakkai Kaiho Vol. 116; no. 10; pp. 1114 - 1119
• Main Authors: Hiraga, Yukihiro, Kou, Junichi, Shimomura, Shinichi
• Format: Journal Article
• Language: Japanese
• Published: Japan The Oto-Rhino-Laryngological Society of Japan, Inc 01.10.2013
• Subjects: Adult; angioimmunoblastic T-cell lymphoma; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; cervical tumor, soluble interleukin-2 receptor; Combined Modality Therapy; Female; Head and Neck Neoplasms - pathology; Head and Neck Neoplasms - therapy; Humans; Immunoblastic Lymphadenopathy - pathology; Immunoblastic Lymphadenopathy - therapy; Lymphoma, T-Cell - pathology; Lymphoma, T-Cell - therapy; Neoplasm Recurrence, Local - therapy; Receptors, Interleukin-2 - metabolism; Treatment Outcome
• ISSN: 0030-6622; 1883-0854
• DOI: 10.3950/jibiinkoka.116.1114

A case of angioimmmunoblastic T-cell lymphoma (AITL) is herein reported. The patient was a 33-year-old female who presented with a tumor arising in the rear of the left lobe of the thyroid. Total removal of the tumor was easily undertaken. Histopathological examinations with Anti-CD3, CD10, CD45RO positive stainings confirmed the diagnosis of AITL. After the determination of stage-categories with IA, 3 courses of chemotherapy with CHOP were administered followed by X-ray irradiation of the cervix with 40 Gy. Thereafter close follow-up has not revealed any recurrence. Serum levels of soluble IL-2 receptor (sIL-2R) gradually decreased according to the round of treatments. AITL is a rare clinical entity included in 1.2-2.5% of non-Hodgkin's lymphomas, which has not at all been reported in the issues concerning otorhinolaryngology. Clinical symptoms and findings include general lymphoadenopathy, hepatosplenomegaly, skin rash, anemia and hypergannmagloburinemia. Diagnosis is determined by histopathological, immunohistochemical and clonality examination. Chemotherapy regimens using multi-agents combined with anthracycline i.e. CHOP have been playing the fundamental role in the therapeutic paradigm, but because of the poorer survival of 20-50% at the 5-year point, AITL is classified as a high-grade malignancy.